MedTrace Logo

The Development, Validation and Application of a Novel Questionnaire Developed by ZOE Ltd Measuring Menopause Symptoms and Subjective Quality of Life

NCT06800560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2025-01-30

No results posted yet for this study

Summary

The MenoScale has been developed from the most common symptoms identified in over 70,000 women to reflect symptom prevalence and user-friendly terminology. It builds and improves on pre-existing scoring tools in four main ways. Firstly, the symptoms assessed are informed by prevalence, as identified from a large cohort. Secondly, the language used to ask about symptoms is modern and accessible as determined through qualitative user research. Thirdly, the impact on quality of life is assessed. Finally, it is already being offered online and completely open access.

The overall aim of this study is to validate the reliability and validity of the MenoScale as an instrument to measure menopausal symptoms and the related subjective impact on quality of life (QoL).

Conditions

Interventions

OTHER

MenoScale

Menopause symptom questionnaire

OTHER

Greene Climacteric Scale

Menopause symptom questionnaire

OTHER

RAND 36-Item Health Survey 1.0

Quality of life questionnaire

OTHER

PREDICT-FFQ-v1

Food frequency questionnaire

Sponsors & Collaborators

  • Zoe Global Limited

    lead OTHER

Principal Investigators

  • Sarah Berry, PhD · King's College London

Eligibility

Min Age
37 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-12
Primary Completion
2024-12-11
Completion
2024-12-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06800560 on ClinicalTrials.gov